Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB 824)
Text and Data Mining valid from 2018-09-06
Received: 1 July 2018
Accepted: 19 August 2018
First Online: 6 September 2018
Ethics approval and consent to participate
: The administration of <sup>68</sup>Ga-Pentixafor was administered in compliance with §37 of the Declaration of Helsinki and the German Medicinal Products Act (AMG §13, 2b) according to the German law and was notified to the local responsible regulatory authority (Regierung von Oberbayern). Prior to the investigation, written informed consent was obtained from all patients. Retrospective data analysis was approved by the local responsible ethics committee of the Technical University Munich.
: Not applicable
: HJ Wester is CEO of Scintomics, Distributor of Pentixafor. The other authors declare that they have no competing interests.Parts of these results were presented at the EANM congress 2017 and consequently presented as an abstract.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.